These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32783513)

  • 1. Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer.
    Recondo G; Mezquita L
    Future Oncol; 2020 Aug; 16(23):1659-1664. PubMed ID: 32783513
    [No Abstract]   [Full Text] [Related]  

  • 2. Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective).
    Teixido C; Reguart N
    Future Oncol; 2020 Aug; 16(23):1677-1681. PubMed ID: 32407147
    [No Abstract]   [Full Text] [Related]  

  • 3. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of Bevacizumab With Cancer Immunotherapy.
    Chen DS; Hurwitz H
    Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
    Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
    Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
    Marrocco I; Romaniello D; Yarden Y
    Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rethink for IO Biomarkers.
    Cancer Discov; 2018 Nov; 8(11):1342. PubMed ID: 30291127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
    Kareva I
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
    De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
    Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
    Romano G; Gawlinski A
    Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges faced when identifying patients for combination immunotherapy.
    Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
    Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.
    Chu DT; Bac ND; Nguyen KH; Tien NLB; Thanh VV; Nga VT; Ngoc VTN; Anh Dao DT; Hoan LN; Hung NP; Trung Thu NT; Pham VH; Vu LN; Pham TAV; Thimiri Govinda Raj DB
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade immunotherapy for cancer comes of age.
    Brower V
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745014
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy-based combinations: an update.
    Fucà G; de Braud F; Di Nicola M
    Curr Opin Oncol; 2018 Sep; 30(5):345-351. PubMed ID: 29994900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.
    Rodriguez-Vida A; Perez-Gracia JL; Bellmunt J
    Clin Cancer Res; 2018 Dec; 24(24):6115-6124. PubMed ID: 29991503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
    Fortis SP; Kotsakis A; Le Tourneau C; Tsitsilonis OE; Georgoulias V; Baxevanis CN
    Cancer Immunol Immunother; 2019 Aug; 68(8):1391-1400. PubMed ID: 31309256
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
    Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
    Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Immunotherapy Combinations.
    Bashir B; Wilson MA
    Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.